Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been r...

Descripción completa

Detalles Bibliográficos

Autores principales:	Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	AboutScience Srl 2024-06-01
Colección:	AboutOpen
Materias:	Analysis Biosimilar Budget impact cost Italian NHS Natalizumab Relapsing-Remitting Multiple Sclerosis
Acceso en línea:	https://journals.aboutscience.eu/index.php/aboutopen/article/view/3078
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!